Divestiture, Agreement, Acquisition, Home Health Assessment, and Quarterly Report - Research Report on Osiris, Clovis, PDL, Amedisys, and Acadia Healthcare Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, October 24, 2013 NEW YORK, October 24, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Osiris Therapeutics, Inc. (NASDAQ: OSIR), Clovis Oncology, Inc. (NASDAQ: CLVS), PDL BioPharma, Inc. (NASDAQ: PDLI), Amedisys Inc. (NASDAQ: AMED), and Acadia Healthcare Company, Inc. (NASDAQ: ACHC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Osiris Therapeutics, Inc. Research Report On October 10, 2013, Osiris Therapeutics, Inc. (Osiris) announced that it has entered into an agreement with a wholly-owned subsidiary of Mesoblast Limited for the sale of its culture-expanded mesenchymal stem cell (ceMSC) business, including Prochymal. According to Osiris, the transaction is worth up to $100 million in initial consideration and milestone payments, with additional royalty payments on sales of Prochymal and other products utilizing the acquired ceMSC technology. Peter Friedli, Chairman of Osiris, stated, "With this transaction, we will focus our business on those areas that are of greatest commercial value to Osiris moving forward." Friedli continued, "Furthermore, we have substantially strengthened our balance sheet, reduced R&D expense and preserved future value from Prochymal through a series of milestone and royalty payments." The Company further reported that it expects to record the closing and asset transfer consideration of $51 million in Q4 FY 2013. The Full Research Report on Osiris Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/82ba_OSIR] -- Clovis Oncology, Inc. Research Report On October 21, 2013, Clovis Oncology, Inc. (Clovis) announced that it has signed an agreement with QIAGEN for the development of a companion diagnostic test to identify the T790M resistance mutation in patients with epidermal growth factor receptor (EGFR) driven non-small cell lung cancer (NSCLC) for CO-1686. Clovis reported that the Companies have also signed a non-exclusive Master Collaboration Agreement which will enable additional Clovis assets requiring supporting companion diagnostic assays to be rapidly developed using QIAGEN sample and assay technologies where appropriate. The Full Research Report on Clovis Oncology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/6a2a_CLVS] -- PDL BioPharma, Inc. Research Report On October 21, 2013, PDL BioPharma, Inc. (PDL) announced that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed, in exchange for a $240.5 million cash payment. PDL reported that it will receive all royalty and milestone payments due under the agreements until it has received payments equal to two times the cash payment made to Depomed, after which all the payments received will be shared evenly between PDL and Depomed. According to the Company, it has also acquired certain rights to royalties and milestones on Depomed's Acuform, which is currently in development by Boehringer Ingelheim and Janssen Pharmaceutica. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/066b_PDLI] -- Amedisys Inc. Research Report On October 4, 2013, Amedisys Inc. (Amedisys) announced that Michael Fleming, MD, FAAFP and Chief Medical Officer for Amedisys, responded to the recent Journal of the American Medical Association (JAMA) article, "The Future of the Medicare Home Health Program," authored by Steven Landers, MD. Fleming stated, "I applaud Dr. Landers, not only for his assessment that the Affordable Care Act offers opportunities for improving the value of home healthcare, but that further reforms are necessary to ensure that older Americans get the home support they need and Medicare gets value." He continued, "The value of home healthcare is little recognized and largely misunderstood. Many have overlooked the advantages it represents for millions of Americans, especially the elderly, chronically ill population. I believe the leaders in our industry, Amedisys included, must begin to support objective research into the program's efficacy and areas for improvement. Only then will we be able to prove the value of the skilled care we provide in the home each day." The Full Research Report on Amedisys Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/56b5_AMED] -- Acadia Healthcare Company, Inc. Research Report On October 15, 2013, Acadia Healthcare Company, Inc. (Acadia Healthcare) announced that it will release its Q3 2013 earnings results after the market close on Tuesday, October 29, 2013. Acadia reported that the Q3 2013 conference call will be held on Wednesday, October 30, 2013 at 9:00 a.m. ET. The Company further informed that interested parties may access the live broadcast through the Investors section on its website, wherein a replay will also be available until November 12, 2013. The Full Research Report on Acadia Healthcare Company, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/c556_ACHC] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Divestiture, Agreement, Acquisition, Home Health Assessment, and Quarterly Report - Research Report on Osiris, Clovis, PDL,
Press spacebar to pause and continue. Press esc to stop.